BuyDomino Search Change Region Menu

Bart Vansteenkiste

avatarAlt

Bart Vansteenkiste has worked for Domino for over 12 years in different commercial roles. A master degree of Electromechanical Engineering and his former role as Pharmaceutical and OEM key account manager for Belgium gave him the perfect background to join the headquarters based FMD group in 2011. Within this group Bart is focussing on the legislative and technical challenges facing the healthcare sector. Bart regularly attends and presents at conferences across Europe on behalf of Domino. Bart is fluent in Dutch, English, French and Spanish. 

Articles from Bart Vansteenkiste

Become compliant with the Russian cryptocode legislation

Time is running out for companies to prepare for the new Russian coding legislation. Here is everything you need to know about becoming compliant.

BLOG

Covid-19: Key considerations when printing onto masks

Understanding how to add the necessary codes to masks is crucial for manufacturers – both for the efficiency of their business and the safety of their customers. There are health risks associated with incorrect coding practices. And different types of mask have different coding requirements. Let’s outline the key considerations.

BLOG

EU Falsified Medicines Directive - Q and A

Bart Vansteenkiste, European Life Sciences Sector Manager answers some general Question about European Union Falsified Medicines Directive.

BLOG

The future of pharmaceutical data management

Pharmaceutical serialisation requires every medication bottle or pack to be tracked from production line to patient. This creates a major data management challenge affecting almost every business function. Here’s what you need to know.

BLOG

Other Pharma Emerging Legislation

The pharmaceutical sector is facing its greatest challenge to date; how to reduce the number of counterfeit and falsified medicines entering the legitimate supply chain.

BLOG

EU Falsified Medicines Directive (FMD 2011/62/EU)

​Adopted in 2011 the EU Falsified Medicines Directive (FMD 2011/62/EU) aims to decrease incidents of falsified medicines reaching the open market within the European Economic area resulting in improved patient safety.

BLOG